Patient P-02154
Therapy response
Improving
Tolerance
Stable
GI state
Deteriorating
Inflammatory state
Stable
Nutritional resilience
Stable
Discontinuation risk
48%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S16
- Day 91 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 122 CR-01 recommended — Clinician Review CR-01
- Day 123 Patient accepted — Started CR-01 in the companion
- Day 128 Deterioration detected before clinical escalation — Clinician Review CR-01
What changed?
Trajectory began diverging from predicted response on Day 91.
Primary contributors, last 14 days
- GI instability+6
- Treatment adherence-4
- Toxicity+4
- Inflammatory activity+3
- Nutritional resilience-2
What helped?
- Clinician Review CR-01Day 122Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
51%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 69% showed improvement
- median effect visible after 10 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable20 min
worsening · -1.1 vs previous 14 d
Sleep duration
Wearable5.6 h
stable · -0.2 vs previous 14 d
Energy level
Daily log3.2/10
worsening · -0.3 vs previous 14 d
Steps
Wearable3,142
worsening · -205 vs previous 14 d
GI burden
Companion38.9/100
worsening · +8.2 vs previous 14 d
Adherence
Companion71.7 %
worsening · -7.2 vs previous 14 d
Sleep quality
Wearable29/100
worsening · -5.9 vs previous 14 d
Glucose, CGM daily mean
CGM147 mg/dL
stable · +3.2 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 49 from the failing basin, 38 from restoration.
Would help
- NP-02 Dietary Support Protocol61% improved among 31 similar · onset 10 d · confidence 57%
- SC-12 Supportive Compound72% improved among 25 similar · onset 6 d · confidence 57%
- DT-01 Dosing / Timing Recommendation86% improved among 7 similar · onset 5 d · confidence 57%
- More proteinGI -7.6 next day on high-intake days · n 22
Would not help
- Keep caffeine lowGI +5.9 next day on high-intake days · n 18
- Keep ultra-processed lowGI +5.8 next day on high-intake days · n 14
- Keep fat lowGI +4.8 next day on high-intake days · n 19
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-7.6supporter · 95%
- Caffeine+5.9detractor · 95%
- Ultra-processed food+5.8detractor · 95%
- Dietary fat load+4.8detractor · 95%
- Histamine load+4.7detractor · 95%
- Insoluble fibre+2.4no signal · 34%
- Simple carbohydrates-1.1no signal · 18%
- Alcohol-0.4no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 40/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓70
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- WearableSleep 5.6 h, below personal baseline
- Autonomic recovery ↑65
- WearableResting HR 80 bpm
- Wearable3,142 steps/day
- WearableShort sleep window
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 44
- Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 46
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 3.1 · butyrate capacity 40/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 46 ms
- Sleep
- 5.8 h
- Steps
- 2,739
- Resting HR
- 80 bpm
Daily log: GI score 39, nutritional resilience 47, adherence 72.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02054 | 40% | S01 | CR-01 | improved | 57 |
| P-02410 | 35% | S01 | GI-04 | improved | 55 |
| P-02018 | 31% | S01 | GI-04 | improved | 46 |
| P-02307 | 27% | S01 | — | — | 55 |
| P-02550 | 27% | S01 | — | — | 70 |
| P-02598 | 27% | S01 | — | — | 53 |
| P-02437 | 26% | S01 | — | — | 64 |
| P-02217 | 25% | S01 | — | — | 61 |
| P-02276 | 25% | S01 | — | — | 57 |
| P-02424 | 25% | S01 | — | — | 62 |
| P-02568 | 25% | S01 | — | — | 51 |
| P-02674 | 34% | S02 | NP-02 | improved | 48 |